Graham R. Foster, FRCP, PhD, provides expert opinion on how to avoid the development of HCV resistance with new direct-acting antiviral regimens through a review of 4 patient cases.
The CME discusses appropriate stopping rules, missed doses, managing null responders and the risks and benefits of deferring current HCV therapy.
Click here to view the presentation
*Free registration required
No comments:
Post a Comment